14 completed, 4 terminated, 3 unknown, 2 not yet recruiting. 24 Phase 2, 4 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 14, Terminated 4, Unknown 3, Not yet recruiting 2, Recruiting 1 |
| Phase 1 | 4 | Completed 3, Unknown 1 |
| Phase 3 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
Follow Finasteride: new trials by email Literature Review of Finasteride trials Research Report on Finasteride
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial testosterone cypionate, finasteride, placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 / Phase 3 | Not yet recruiting | VA Office of Research and Development | 300 | 2027-10-01 | 2026-08-04 |
| New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia raloxifene, Finasteride - BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms | Phase 2 | Recruiting | Beth Israel Deaconess Medical Center | 242 | 2025-12-03 | 2026-03-23 |
| Various Procedural Treatment Options for Androgenetic Alopecia topical finasteride, Topical minoxidil - Androgenetic Alopecia | Phase 2 | Not yet recruiting | Sheikh Zayed Medical College | 190 | 2025-02-01 | 2025-02-13 |
| Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia minoxidil + finasteride, Placebo foam - Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA) | Phase 2 | Completed | Beijing Dayspring Pharmaceutical Technology Co., Ltd | 110 | 2024-12-05 | 2026-03-03 |
| Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia Finasteride, Minoxidil - Androgenetic Alopecia | Phase 2 / Phase 3 | Unknown | Universitas Indonesia | 40 | 2023-05-01 | 2023-09-22 |
| A Clinical Trial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of IVL3001 Finasteride 1mg Tablet, IVL3001 - Androgenetic Alopecia | Phase 1 / Phase 2 | Completed | Inventage Lab., Inc. | 40 | 2021-09-21 | 2022-03-04 |
| Testosterone Plus Finasteride Treatment After Spinal Cord Injury Testosterone Enanthate, Finasteride, Placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Terminated | VA Office of Research and Development | 33 | 2017-04-27 | 2023-09-29 |
| A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males Setipiprant, Placebo, Finasteride - Alopecia | Phase 2 | Completed | Allergan | 169 | 2016-07-14 | 2019-04-05 |
| Finasteride Treatment of Severe Nodulocystic Acne Finasteride 23.5 mg tablets, Finasteride 33.5 mg tablets, Placebo tablets - NODULOCYSTIC ACNE | Phase 2 | Completed | Elorac, Inc. | 106 | 2015-07-01 | 2019-02-15 |
| Enzalutamide & Dutasteride/Finasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer. Enzalutamide and Dutasteride or finasteride - Prostate Cancer | Phase 2 | Completed | University of Rochester | 43 | 2014-09-01 | 2024-11-13 |
| Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer finasteride 5mg oral daily - Non-small Cell Lung Cancer | Phase 2 | Terminated | CancerCare Manitoba | 4 | 2014-06-01 | 2018-08-31 |
| Finasteride, Dutasteride and Insulin Action Finasteride, Dutasteride - Healthy Volunteers | Phase 2 | Unknown | University of Birmingham | 12 | 2012-08-01 | 2013-08-14 |
| Finasteride for Chronic Central Serous Chorioretinopathy Finasteride, Placebo - Retinal Disease | Phase 2 | Terminated | National Eye Institute (NEI) | 6 | 2012-04-01 | 2014-12-04 |
| A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Autologous Human Platelet Lysate (HPL), 2 % Minoxidil and /or Finasteride - Androgenetic Alopecia | Phase 1 / Phase 2 | Unknown | Kasiak Research Pvt. Ltd. | 20 | 2012-01-01 | 2012-07-25 |
| Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Finasteride - Retinal Disease | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 3 | 2010-10-01 | 2024-01-30 |
| Oral T7 Oral Testosterone in Man First Intervention (7 days), First Washout (7 days), Second Intervention (7 days) - Healthy Males, Male Contraceptive | Phase 2 | Completed | University of Washington | 11 | 2009-07-01 | 2014-01-13 |
| Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Finasteride - Retinal Disease | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2009-02-01 | 2016-09-26 |
| Selenomethionine and Finasteride Before Surgery or Radiation Therapy in Treating Patients With Stage I or Stage II Prostate Cancer selenomethionine, finasteride, placebo - Prostate Cancer | Phase 2 | Completed | Roswell Park Cancer Institute | 55 | 2008-08-01 | 2023-10-02 |
| The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy Finasteride - Hematuria, Hematospermia | Phase 2 | Terminated | University of British Columbia | 29 | 2008-03-01 | 2014-01-31 |
| Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate) 2.5 mg NX-1207, 0.125 mg NX-1207, finasteride - Benign Prostatic Hyperplasia (BPH), Enlarged Prostate | Phase 2 | Completed | Nymox Corporation | 85 | 2007-05-01 | 2012-06-14 |
Showing 20 of 24. Sign in to see all of them.
Alopecia (6) · Prostatic Neoplasms (5) · Central Serous Chorioretinopathy (3) · Prostatic Hyperplasia (3) · Retinal Diseases (3) · Bone Resorption (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Genital Diseases, Male (2) · Gonadal Disorders (2) · Hypogonadism (2) · Motor Activity (2) · Nervous System Diseases (2) · Spinal Cord Diseases (2) · Spinal Cord Injuries (2)
National Eye Institute (NEI) (3) · VA Office of Research and Development (3) · Allergan (1) · Alliance for Clinical Trials in Oncology (1) · Beijing Dayspring Pharmaceutical Technology Co., Ltd (1) · Beth Israel Deaconess Medical Center (1) · CancerCare Manitoba (1) · Elorac, Inc. (1) · Ente Ospedaliero Ospedali Galliera (1) · Inventage Lab., Inc. (1) · Kasiak Research Pvt. Ltd. (1) · National Cancer Institute (NCI) (1) · Nymox Corporation (1) · Roswell Park Cancer Institute (1) · Sheikh Zayed Medical College (1)
United States (15) · Canada (2) · Australia (1) · China (1) · India (1) · Indonesia (1) · Italy (1) · Pakistan (1) · United Kingdom (1)
Joshua F Yarrow, PhD MS BS (2) · Andrea De Censi, MD (1) · Aria Olumi, MD (1) · Catherine B Meyerle, MD (1) · Catherine Meyerle, M.D. (1) · Cheng Zhou, MD, PhD (1) · Chunkit Fung, M.D. (1) · Dana M Otzel, PhD (1) · Emily Y Chew, M.D. (1) · James L. Mohler, MD (1) · Jeri Kim (1) · Jianzhong Zhang, MD, PhD (1) · Joan-En Lin (1) · Joel Picus, MD (1) · John K Amory, MD, MPH (1)
PMID 20969601, PMID 21273946, PMID 24012740, PMID 24326421, PMID 38833144, PMID 39722695, PMID 40522203
I01RX001449 (1), K23HD045386 (1), N01CN35159 (1), P30CA016672 (1), R01DK142211 (1), U10CA031946 (1), U54HD042454 (1)